Stock Analysis, Dividends, Split History

CCS / Century Communities Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)871.95
Enterprise Value ($M)1,812.74
Book Value ($M)803.71
Book Value / Share26.68
Price / Book1.08
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 29,616,597
Common Stock Shares Outstanding 29,502,624
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.05
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Land Sales And Other Revenue8,503,000.00
Home Building Revenue1,405,443,000.00
Financial Services Revenue9,853,000.00
Real Estate Revenue Net1,413,946,000.00
Net Income50.30
Earnings Per Share Basic2.06
Earnings Per Share Diluted2.03
Cash Flow Statement (mra) ($M)
Cash From Operations-114.65
Cash from Investing-134.45
Cash from Financing-134.45
Identifiers and Descriptors
Central Index Key (CIK)1576940

Split History

Stock splits are used by Century Communities Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

PulteGroup Brings Back Centex to Expand First-Time Buyer Base

8h zacks
Atlanta-based homebuilder PulteGroup, Inc. (PHM - Free Report) announced the relaunch of its Centex brand and plans to develop high quality and affordable home communities in Georgia for first-time buyers. The communities will include smart technology. The latest Centex community, Princeton Village, is now open in Palmetto, GA. It will be followed by new communities in the East Gwinnett and Mill Creek areas of Gwinnett County, and in McDonough in Henry County. (1-0)

KB Home (KBH) Stock Up 18% Over a Year: Can it Gain Further?

16h zacks
Impressive earnings trend, Returns-Focused Growth Plan, and built-to-order approach, along with a healthy housing industry and strong demand bode well for KB Home (KBH - Free Report) . Consequently, shares of the company have gained 18.3% in the past year against its industry’s decline of 1.3%. However, rising costs and interest rate pose concerns. Let’s delve deeper. (11-0)

PulteGroup Teams Up With Builder Boost to Attract Customers

2018-09-14 zacks
Pulte Homes, a national brand of PulteGroup, Inc. (PHM - Free Report) , partners with Builder Boost, an Austin-based online resource and community provider, to unveil its Pulte Smart Home in Austin. Builder Boost sells newly-built homes via social media. Pulte Home will connect every newly-build home with seamless Wi-Fi reliability, along with widened built-in access points and direct wiring throughout the area. (1-0)

Here's Why You Should Buy PulteGroup (PHM) Stock Right Now

2018-09-11 zacks
Undeniably, there have been indications that the thriving housing market is losing steam of late. Factors like increasing construction costs, inadequacy of skilled labor and rising prices of homes owing to higher mortgage rates continue to make things difficult. Despite these headwinds, homebuilder PulteGroup Inc. (PHM - Free Report) is one such company that continues to display strength in several areas and has managed to navigate smoothly. (1-0)

3 Homebuilder Stocks for Value Investors

2018-09-06 investorplace
Value investors searching for industrial goods stocks should look no further than the residential construction sector. Real estate has enjoyed years of robust price growth in several markets across the country. However, labor shortages, rising interest rates and higher real estate prices have slowed the growth of this sector, making many homebuilder stocks a bargain. (1-0)

CUSIP: 156504300